BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Misonix Incorporated (MSON) Announces Achievement of Contract Vendor Status With Select Medical (SLMC)


11/17/2010 7:21:03 AM

FARMINGDALE, N.Y., Nov. 16, 2010 /PRNewswire/ -- Misonix, Inc. (Nasdaq: MSON), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has announced its achievement of contract vendor status with Select Medical Corporation, based in Mechanicsburg, PA, for its SonicOneĀ® Ultrasonic Wound Cleansing and Debridement System. As a result of this status, specialty hospitals, without further approval, can easily arrange for system valuations and issue purchase orders for disposable products, accessories and system rentals.

Select Medical Corporation is an operating unit of Select Medical Holdings (NYSE: SEM), a leading operator of specialty hospitals, including 111 Long Term Acute Care ("LTACH") facilities and 6 Acute Rehabilitation facilities located in 28 states. These facilities operate as Select Specialty Hospitals, Regency Specialty Hospitals and Great Lakes Specialty Hospitals. Select also operates approximately 950 Out Patient Rehabilitation Clinics in 36 states and provides contract Medical Rehabilitation Services to over 400 skilled nursing, assisted living, senior care, school and worksite locations. Misonix's contract vendor status is focused on the LTACH facilities, which provide care and rehabilitation for trauma victims and other serious and complex medical conditions.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"Misonix is excited by the potential for expanded clinical use of our ultrasonic wound management technology via an association with a high caliber organization such as Select Medical," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "The clinical benefits for patient and physician over traditional means of wound cleansing and debridement are evident. This is another example of our commitment to state-of-the-art medical devices for use by the worldwide medical community working in cooperation with highly regarded healthcare providers."

About Misonix:

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Investor Relations Contact:

Kevin McGrath/Cameron Associates, Inc.

212-245-4577

Kevin@cameronassoc.com



SOURCE Misonix, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES